PTO/SB/08B (10-01) 0/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U EPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Applicati n Number	10/010,065	Ш
Filing Date	December 5, 2001	
First Named Inv nt r	ALLEN et al.	-
Art Unit	1645	<del>M</del>
Examiner Name	Unassigned	0
Attorney Docket No.	R-648	Ш 🧷

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS TANG TRADE Cite miner

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the T 2 item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No.1 itials ' number(s), publisher, city and/or country where published. A. SALTIEL, "NEW PERSPECTIVES INTO THE MOLECULAR PATHOGENESIS AND TREATMENT OF TYPE 2 DIABETES," Cell, AA Vol. 104, February 23, 2001, pp. 517-529 R. UNGER et al., "THE ESSENTIAL ROLE OF GLUCAGON IN THE AB PATHOGENESIS OF DIABETES MELLITUS," The Lancet, January 4, 1975, pp. 14-16 R. UNGER, "DIABETES AND THE ALPHA CELL," Diabetes, Vol. 25. AC February 1976, pp. 136-151 R. BURCELIN et al., "CLONING AND SEQUENCE ANALYSIS OF THE MURINE GLUCAGON RECEPTOR-ENCODING GENE." Gene. AD Vol. 164, May 1995, pp. 305-310 C. UNSON et al., "BIOLOGICAL ACTIVITIES OF des-His1[Glu9]GLUCAGON AMIDE, A GLUCAGON ANTAGONIST1," ΑE Peptides, Vol. 10, May 1989, pp. 1171-1177 M. WAKELAM et al., "ACTIVATION OF TWO SIGNAL-ΑF TRANSDUCTION SYSTEMS IN HEPATOCYTES BY GLUCAGON." Nature, Vol. 323, September 4, 1986, pp. 68-71 R. PITTNER et al., "ACTIVATION OF MEMBRANE PROTEIN KINASE C BY GLUCAGON AND Ca2+-MOBILIZING HORMONES AG IN CULTURED RAT HEPATOCYTES," Biochem. J., Vol. 277, March 1991, pp. 371-378 S CHAMBERS et al., "GLUCAGON RECEPTOR GENE MUTATION IN AΗ ESSENTIAL HYPERTENSION" Nature Genetics, Vol. 12, February 1996, pp. 122 J. HAGER et al., "A MISSENSE MUTATION IN THE GLUCAGON RECEPTOR GENE IS ASSOCIATED WITH NON-INSULIN-ΑI DEPENDENT DIABETES MELLITUS," Nature Genetics, Vol. 9, March 1995, pp. 299-304

Examiner Signature	Valley	Date Considered	12.18.02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. **Unsaved Document** 

COPY OF FAPERS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

	١.
Aggregation	4
Approved for use	
U.S. Patent and Trademark Office: I	Ж

PTO/SB/08B (10-01)

ph 10/31/2002. OMB 0651-0031

SEPARTMENT OF COMMERCE

(1	J58	as	many	SHEELS	as	nece:	ssary)
_	_	_					
		2				,	,

or form 14498		TRADEM	U.S. Patent and Trade	Complete if Known	
RMATION DISCLOSURE			Application Number	10/010,065	Ш
			Filing Date	December 5, 2001	>
EMENT BY APPLICANT		First Named Inv nt r	ALLEN et al.		
			Art Unit	1645	<del>- W</del>
ise as man	y sheets as i	necessary)	Examiner Name	Unassigned	<del>- 0</del>
2	of	2	Attorney Docket No.	R-648	111

	Under th	ne Paperwork Redu	uction Act (1)1995, no pe	rsons are required to respond to a collection	of information unless it contains a valid	OMB control numbe	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		EM	Complete if Known				
		Application Number	10/010,065	ш	8		
		Filing Date	December 5, 2001	> <	9		
		First Named Inv nt r	ALLEN et al.		<b>1</b> 65		
	(vice on many shorts are assessed)		Art Unit	1645		1 =	
			Unassigned	<del>- 0 -</del>	CH CENTER 1600/2900		
Sheet	2	of	2	Attorney Docket No.	R-648	ш 🤈	, <u>±</u>
							ည
		01	THER PRIOR AF	T NON PATENT LITERATI	URE DOCUMENTS		一
Examiner Initials * Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				le of the ssue	T²		
1/1		S. LOK et al., "THE HUMAN GLUCAGON RECEPTOR ENCODING			NG		
l √Y5	AJ	GENE: STRUCTURE, CDNA SEQUENCE AND CHROMOSOMAL					
ソ	LOCALIZATION" Gene, Vol. 140, 1994, pp. 203-209						
10		S. MENZEL et al., "LOCALIZATION OF THE GLUCAGON					
W	AK	1	RECEPTOR GENE TO HUMAN CHROMOSOME BAND 17q25"				
<b>"</b>	Genomics, Vol. 20, 1994, pp. 327-328						

3 0 2002

COPYOF	PAPERS
OFIG!NAL	LY FILED

Examiner Signature	14/22	Date Considered	12.18.02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. **Unsaved Document** 

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.